Reina Asaga

Dr. Reina Asaga


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MIMasashi Ishihara
Masashi Ishihara
HCHao Chen
Hao Chen
RAReina Asaga
Reina Asaga
HSHikaru Suzuki
Hikaru Suzuki
SYShinichiro Yamamoto
Shinichiro Yamamoto
Nobuhiko SekiNobuhiko Seki
Nobuhiko Seki
Background: Reliable and readily accessible prognostic biomarkers for extensive-stage small-cell lung cancer (ES-SCLC) are still lacking. The neutrophil-to-lymphocyte ratio (NLR), a marker of systemic inflammation, has shown prognostic relevance in several malignancies; however, its dynamic changes during treatment have not been well characterized in SCLC. Methods: We retrospectively analyzed patients with ES-SCLC who received systemic chemotherapy between January 2010 and December 2024. Baseline NLR was calculated within 7 days before first-line treatment, and on-treatment NLR was assessed at 6 weeks. A predefined NLR cutoff value of 5 was applied, and changes in NLR (ΔNLR) were defined as the difference between 6-week and baseline values. Associations with time to treatment failure (TTF) and overall survival (OS) were evaluated. Results: A total of 176 patients were enrolled. High baseline NLR (≥5) was significantly associated with shorter TTF and OS (both p < 0.01). An increase in NLR during treatment (ΔNLR ≥ 0) was significantly associated with poorer OS. Combined assessment of baseline NLR and ΔNLR identified distinct prognostic groups, with patients exhibiting both high baseline NLR and ΔNLR ≥ 0 demonstrating markedly poor survival. In multivariate analyses, baseline NLR, ΔNLR, performance status, and immune checkpoint inhibitor combination therapy were independent predictors of survival. Baseline NLR analyzed as a continuous variable showed a significant inverse correlation with TTF and OS. Conclusions: Combined evaluation of baseline NLR and its on-treatment change provides improved prognostic stratification in patients with ES-SCLC.